Anacor Pharmaceuticals News
The most recent short interest data has been released by the NASDAQ for the 11/29/2013 settlement date, which shows a 250,583 share increase in total short interest for Anacor Pharmaceuticals Inc , to 2,636,306, an increase of 10.50% since 11/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. Last Tuesday, Annaly Capital Management (NLY)'s Co-CIO, Rose-marie Lyght, made a $206,101 purchase of
DELAFIELD, Wis. (Stockpickr) -- Trading stocks that trigger major breakouts can lead to massive profits. Once a stock trends to a new high, or takes o...
The top 10 open-market insider purchases and sales filed at the SEC Wednesday.
PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company's Chief Financial Officer, will provide a company overview at the 25th Annual Piper ...
Anacor Pharmaceuticals announced today that Geoff Parker, the company’s Chief Financial Officer, will provide a company overview at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 12:00 p.m.
Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.